Influential Scientific Information

This site provides information on the independent peer review of documents defined by the Centers for Disease Control and Prevention’s (CDC’s) viral hepatitis program as influential in terms of their potential impact on public policy or the private sector. CDC makes this information available to demonstrate its efforts to utilize only the most transparent and independent peer review, appropriate research methods, and the highest level of data quality. In addition, this information demonstrates the viral hepatitis program’s compliance with the specific requirements of the Information Quality Act (2019), and of peer-review standards developed by the Office of Management and Budget (OMB), the U.S. Department of Health and Human Services (DHHS), and CDC. The OMB requirements, described in this White House memo, include making publicly available specific information on the peer review of influential scientific documents disseminated by the federal government. OMB has defined two special categories of influential information: Influential Scientific Information (ISI) and Highly Influential Scientific Assessments (HISAs). At this time, CDC’s viral hepatitis program only has documents deemed ISI.

For issues related to CDC’s viral hepatitis program’s peer-review agenda please contact:

Division of Viral Hepatitis
Associate Director for Science
Centers for Disease Control and Prevention
National Center for HIV, Viral Hepatitis, STD, and TB Prevention
1600 Clifton Road, NE MS US12-3
Atlanta, GA 30333

View other CDC Peer Review Agenda Documents

Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children – United States, 2023

Recommendations for Hepatitis B Screening and Testing – United States, 2023

Recommendations for Hepatitis C Screening Among Adults – 2020